| Followers | 1022 |
| Posts | 41349 |
| Boards Moderated | 2 |
| Alias Born | 04/27/2015 |
Tuesday, April 07, 2026 4:40:39 PM
I only had Charles Scwab and could not trade A*IXI and missed out on hundreds of thousands because I saw it starting to move in $.11-12 range but couldnt but it...Now made an ETRADE account that allows you to buy the NASDAQ Pennies that Charles Schwab wont let you buy....you can buy this one on Schwab......still cheap here....
Recent QNCX News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:25:02 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/17/2026 08:53:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 01:23:02 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 08:30:02 PM
- Quince Therapeutics settles $16.4M debt with $5.5M payment • IH Market News • 03/30/2026 02:26:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 12:35:07 PM
- Quince Therapeutics Settles Approximately $16.4 Million of Debt • Business Wire • 03/30/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:45:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 11:06:31 AM
- Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives • Business Wire • 02/09/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2026 09:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 09:40:03 PM
- Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia • Business Wire • 01/29/2026 08:10:00 PM
- Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting • Business Wire • 01/28/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2026 01:05:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 11:10:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 11:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 10:59:06 PM
- Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia • Business Wire • 12/15/2025 01:00:00 PM
- Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders • Business Wire • 12/10/2025 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 01:12:05 PM
- Quince Therapeutics to Participate at Investor Events in December 2025 • Business Wire • 11/24/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 09:05:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 09:05:30 PM
- Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results • Business Wire • 11/12/2025 09:05:00 PM
